Lane Earl Cox wins allergy blood test account
pharmafile | April 16, 2010 | News story | Medical Communications | LEC, Phadia, allergy
Healthcare advertising agency Lane Earl & Cox has won the account to promote an allergy blood test product from diagnostics company Phadia.
ImmunoCap is a blood test which identifies specific allergens for patients with suspected allergic symptoms. Confirming atopy (allergic hypersensitivity) together with identifying the specific allergens enables better management of a wide range of common diseases including asthma, rhinitis and eczema.
Food allergies with their significant impact and threat to life are particularly suitable for ImmunoCap. Phadia says the test is very safe and highly sensitive, and is able to identify the severity of the reaction and cross reactivity.
Commenting, LEC’s Managing Director Mike Lane said: “This win is important to the agency as it is consistent with our plans to expand into other health- related areas so as to lessen our reliance on our traditional pharmaceutical sector.
The agency won the pitch to promote ImmunoCap against strong competition, and Mike Lane says he has first hand experience of allergies.
“I’m particularly pleased as seasonal rhinitis is something I have suffered from since I was a boy and anything we can do to help similar patients, I’m sure will be welcomed by them,” said Mike.
Pamela Pirrit, Phadia’s Product Manager commented: “I am really pleased to be working with LEC on this project. Their pitch combined imagination with professionalism, bringing in creativity and appropriate digital touch-points and we are all very excited about bringing the allergy-testing message to the health care community”.
Related Content
Roche shares data from phase 3 trial of Xolair as allergy treatment
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase …
FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment
US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s …
Camallergy awarded £1.1m government funding for peanut allergy immunotherapy
Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today …
